{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T16:44:01Z","timestamp":1783183441829,"version":"3.54.6"},"reference-count":71,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2016,11,1]],"date-time":"2016-11-01T00:00:00Z","timestamp":1477958400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Eli Lilly Italia SpA"}],"content-domain":{"domain":["nmcd-journal.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nutrition, Metabolism and Cardiovascular Diseases"],"published-print":{"date-parts":[[2016,11]]},"DOI":"10.1016\/j.numecd.2016.07.006","type":"journal-article","created":{"date-parts":[[2016,7,14]],"date-time":"2016-07-14T23:29:58Z","timestamp":1468538998000},"page":"963-970","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"title":["Genitourinary infections in diabetic patients in the new era of diabetes therapy with sodium-glucose cotransporter-2 inhibitors"],"prefix":"10.1016","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2081-8542","authenticated-orcid":false,"given":"M.","family":"Rizzi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Trevisan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.numecd.2016.07.006_bib1","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.jdiacomp.2014.11.005","article-title":"Diabetes mellitus and infections: an evaluation of hospital utilization and management costs in the Unites States","volume":"29","author":"Korbel","year":"2015","journal-title":"J Diabetes Complicat"},{"key":"10.1016\/j.numecd.2016.07.006_bib2","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.2105\/AJPH.81.9.1158","article-title":"Cause-specific mortality in a population-based study of diabetes","volume":"81","author":"Moss","year":"1991","journal-title":"Am J Public Health"},{"key":"10.1016\/j.numecd.2016.07.006_bib3","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.2337\/diacare.21.7.1138","article-title":"Mortality in adults with and without diabetes in a national cohort of the US population, 1971\u20131993","volume":"21","author":"Gu","year":"1998","journal-title":"Diabetes Care"},{"key":"10.1016\/j.numecd.2016.07.006_bib4","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.2337\/diacare.24.6.1044","article-title":"Diabetes and the risk of infection-related mortality in the U.S.","volume":"24","author":"Bertoni","year":"2001","journal-title":"Diabetes Care"},{"key":"10.1016\/j.numecd.2016.07.006_bib5","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/dmrr.682","article-title":"Common infections in diabetes: pathogenesis, management and relationship to glycaemic control","volume":"23","author":"Peleg","year":"2007","journal-title":"Diabetes Metab Res Rev"},{"key":"10.1016\/j.numecd.2016.07.006_bib6","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1056\/NEJM199912163412507","article-title":"Infections in patients with diabetes mellitus","volume":"341","author":"Joshi","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.numecd.2016.07.006_bib7","doi-asserted-by":"crossref","first-page":"510","DOI":"10.2337\/diacare.26.2.510","article-title":"Quantifying the risk of infectious diseases for people with diabetes","volume":"26","author":"Shah","year":"2003","journal-title":"Diabetes Care"},{"key":"10.1016\/j.numecd.2016.07.006_bib8","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1086\/431587","article-title":"Increased risk of common infections in patients with type 1 and type 2 diabetes mellitus","volume":"41","author":"Muller","year":"2005","journal-title":"Clin Infect Dis"},{"issue":"3","key":"10.1016\/j.numecd.2016.07.006_bib9","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.diabet.2012.01.002","article-title":"Diabetes and mucormycosis: a complex interplay","volume":"38","author":"Rammaert","year":"2012","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.numecd.2016.07.006_bib10","doi-asserted-by":"crossref","first-page":"271","DOI":"10.2337\/diab.39.3.271","article-title":"Handicaps to host defense. Effects of hyperglycemia on C3 and Candida albicans","volume":"39","author":"Hostetter","year":"1990","journal-title":"Diabetes"},{"key":"10.1016\/j.numecd.2016.07.006_bib11","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1086\/501830","article-title":"The association of diabetes and glucose control with surgical-site infections among cardiothoracic surgery patients","volume":"22","author":"Latham","year":"2001","journal-title":"Infect Control Hosp Epidemiol"},{"key":"10.1016\/j.numecd.2016.07.006_bib12","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1507\/endocrj.49.531","article-title":"Perioperative hyperglycemia is a strong correlate of postoperative infection in type II diabetic patients after coronary artery bypass grafting","volume":"49","author":"Guvener","year":"2002","journal-title":"Endocr J"},{"key":"10.1016\/j.numecd.2016.07.006_bib13","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.2106\/JBJS.H.00116","article-title":"The impact of glycemic control and diabetes mellitus on perioperative outcomes after total joint arthroplasty","volume":"91","author":"Marchant","year":"2009","journal-title":"J Bone Jt Surg Am"},{"key":"10.1016\/j.numecd.2016.07.006_bib14","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1016\/j.ajem.2014.08.071","article-title":"Prognostic determinants of community-acquired bloodstream infection in type 2 diabetic patients in ED","volume":"32","author":"Yo","year":"2014","journal-title":"Am J Emerg Med"},{"key":"10.1016\/j.numecd.2016.07.006_bib15","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/S2213-8587(15)00379-4","article-title":"Diabetes and infection: assessing the association with glycaemic control in population-based studies","volume":"4","author":"Pearson-Stuttard","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.numecd.2016.07.006_bib16","doi-asserted-by":"crossref","first-page":"369","DOI":"10.2337\/dc10-1771","article-title":"Use of dipeptidyl peptidase-4 inhibitors and the reporting of infections: a disproportionality analysis in the World Health Organization VigiBase","volume":"34","author":"Willemen","year":"2011","journal-title":"Diabetes Care"},{"key":"10.1016\/j.numecd.2016.07.006_bib17","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1472-6823-10-7","article-title":"Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes","volume":"10","author":"Williams-Herman","year":"2010","journal-title":"BMC Endocr Disord"},{"key":"10.1016\/j.numecd.2016.07.006_bib18","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1111\/j.1463-1326.2012.01565.x","article-title":"Safety and tolerability of linagliptin: a pooled analysis of data from randomized controlled trials in 3572 patients with type 2 diabetes mellitus","volume":"14","author":"Schernthaner","year":"2012","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.numecd.2016.07.006_bib19","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1111\/j.1463-1326.2012.01610.x","article-title":"Longer term safety of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus: systematic review and meta-analysis","volume":"14","author":"Go\u00dfen","year":"2012","journal-title":"Diabetes, Obes Metab"},{"key":"10.1016\/j.numecd.2016.07.006_bib20","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1016\/j.numecd.2014.07.014","article-title":"Drug utilization, safety, and effectiveness of exenatide, sitagliptin, and vildagliptin for type 2 diabetes in the real world: data from the Italian AIFA Anti-diabetics Monitoring Registry","volume":"24","author":"Montilla","year":"2014","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"12","key":"10.1016\/j.numecd.2016.07.006_bib21","doi-asserted-by":"crossref","first-page":"e005752","DOI":"10.1136\/bmjopen-2014-005752","article-title":"Safety and effectiveness of dipeptyl peptidase-4 inhibitors versus intermediate-acting insulin or placebo for patients with type 2 diabetes failing two oral antihyperglycaemic agents: a systematic review and network meta-analysis","volume":"4","author":"Tricco","year":"2014","journal-title":"BMJ Open"},{"key":"10.1016\/j.numecd.2016.07.006_bib22","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1093\/clinids\/21.2.316","article-title":"Prevalence of asymptomatic bacteriuria and associated host factors in women with diabetes mellitus","volume":"21","author":"Zhanel","year":"1995","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.numecd.2016.07.006_bib23","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.2337\/diacare.23.12.1737","article-title":"Risk factors for symptomatic urinary tract infection in women with diabetes","volume":"23","author":"Geerlings","year":"2000","journal-title":"Diabetes Care"},{"key":"10.1016\/j.numecd.2016.07.006_bib24","doi-asserted-by":"crossref","first-page":"e41","DOI":"10.1086\/381755","article-title":"Asymptomatic bacteriuria in women with diabetes: influence of metabolic control","volume":"38","author":"Bonadio","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.numecd.2016.07.006_bib25","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1093\/oxfordjournals.aje.a000181","article-title":"Risk of urinary tract infection and asymptomatic bacteriuria among diabetic and nondiabetic postmenopausal women","volume":"161","author":"Boyko","year":"2005","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.numecd.2016.07.006_bib26","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/j.1464-5491.2005.01758.x","article-title":"Prevalence and risk factors for asymptomatic bacteriuria in women with type 2 diabetes mellitus","volume":"23","author":"Ishay","year":"2006","journal-title":"Diabet Med"},{"key":"10.1016\/j.numecd.2016.07.006_bib27","doi-asserted-by":"crossref","first-page":"230","DOI":"10.2337\/dc10-0421","article-title":"Meta-analysis of the significance of asymptomatic bacteriuria in diabetes","volume":"34","author":"Renko","year":"2011","journal-title":"Diabetes Care"},{"key":"10.1016\/j.numecd.2016.07.006_bib28","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1001\/archinte.166.20.2222","article-title":"Asymptomatic bacteriuria in women with diabetes mellitus: effect on renal function after 6 years of follow-up","volume":"166","author":"Meiland","year":"2006","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.numecd.2016.07.006_bib29","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1056\/NEJMoa021042","article-title":"Antimicrobial treatment in diabetic women with asymptomatic bacteriuria","volume":"347","author":"Harding","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.numecd.2016.07.006_bib30","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1086\/600883","article-title":"Long-term Escherichia coli asymptomatic bacteriuria among women with diabetes mellitus","volume":"49","author":"Dalal","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.numecd.2016.07.006_bib31","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD009534.pub2","article-title":"Antibiotics for asymptomatic bacteriuria (review)","volume":"4","author":"Zalmanovici","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.numecd.2016.07.006_bib32","doi-asserted-by":"crossref","first-page":"120","DOI":"10.4103\/0971-4065.65315","article-title":"Prevalence of lower urinary tract infection in South Indian type 2 diabetic subjects","volume":"20","author":"Janifer","year":"2010","journal-title":"Indian J Nephrol"},{"key":"10.1016\/j.numecd.2016.07.006_bib33","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.jdiacomp.2012.06.008","article-title":"Incidence of urinary tract infection among patients with type 2 diabetes in the UK General Practice Research Database (GPRD)","volume":"26","author":"Hirji","year":"2012","journal-title":"J Diabetes Complicat"},{"key":"10.1016\/j.numecd.2016.07.006_bib34","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.jdiacomp.2014.03.012","article-title":"Disease burden of urinary tract infections among type 2 diabetes mellitus patients in the U.S.","volume":"28","author":"Yu","year":"2014","journal-title":"J Diabetes Complicat"},{"key":"10.1016\/j.numecd.2016.07.006_bib35","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1086\/427507","article-title":"Infectious diseases Society of America guidelines for the diagnosis and treatment of asymptomatic bacteriuria in adults","volume":"40","author":"Nicolle","year":"2005","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.numecd.2016.07.006_bib36","doi-asserted-by":"crossref","first-page":"29","DOI":"10.4066\/AMJ.2014.1906","article-title":"Clinical profile of urinary tract infecions in diabetics and non-diabetics","volume":"7","author":"Aswani","year":"2014","journal-title":"Australas Med J"},{"key":"10.1016\/j.numecd.2016.07.006_bib37","first-page":"281","article-title":"Diabetes mellitus and bactaeremia: a comparative study between diabetic and non-diabetic patients","volume":"5","author":"Carton","year":"1992","journal-title":"Eur J Med"},{"key":"10.1016\/j.numecd.2016.07.006_bib38","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.jdiacomp.2010.01.002","article-title":"Change from oral antidiabetic therapy to insulin and risk of urinary tract infections in type 2 diabetic patients: a population-based prescription study","volume":"24","author":"Sanden","year":"2010","journal-title":"J Diabetes Complicat"},{"key":"10.1016\/j.numecd.2016.07.006_bib39","doi-asserted-by":"crossref","first-page":"744","DOI":"10.2337\/diacare.23.6.744","article-title":"Asymptomatic bacteriuria may be considered a complication in women with diabetes","volume":"23","author":"Geerlings","year":"2000","journal-title":"Diabetes Care"},{"key":"10.1016\/j.numecd.2016.07.006_bib40","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1097\/01.ASN.0000092790.89332.D2","article-title":"Molecular analysis of the SGLT2 gene in patients with renal glucosuria","volume":"14","author":"Santer","year":"2003","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.numecd.2016.07.006_bib41","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1056\/NEJM199608153350703","article-title":"A prospective study of risk factors for symptomatic urinary tract infection in young women","volume":"335","author":"Hooton","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.numecd.2016.07.006_bib42","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1086\/315827","article-title":"Risk factors for recurrent urinary tract infection in young women","volume":"182","author":"Scholes","year":"2000","journal-title":"J Infect Dis"},{"key":"10.1016\/j.numecd.2016.07.006_bib43","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1023\/A:1012263304999","article-title":"Virulence factors of Escherichia coli isolated from urine of diabetic women with asymptomatic bacteriuria: correlation with clinical characteristics","volume":"80","author":"Geerlings","year":"2001","journal-title":"Ant Van Leeuwenhoek"},{"key":"10.1016\/j.numecd.2016.07.006_bib44","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1111\/j.1464-5491.2004.01169.x","article-title":"Diabetes mellitus in itself is not a risk factor for antibiotic resistance in Escherichia coli isolated from patients with bacteriuria","volume":"21","author":"Meiland","year":"2004","journal-title":"Diabet Med"},{"key":"10.1016\/j.numecd.2016.07.006_bib45","doi-asserted-by":"crossref","first-page":"33","DOI":"10.3810\/pgm.2013.05.2650","article-title":"Genital mycotic infections in patients with diabetes","volume":"125","author":"Nyirjesy","year":"2013","journal-title":"Postgrad Med"},{"key":"10.1016\/j.numecd.2016.07.006_bib46","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1067\/mob.2002.126285","article-title":"Impaired tolerance for glucose in women with recurrent vaginal candidiasis","volume":"187","author":"Donders","year":"2002","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.numecd.2016.07.006_bib47","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1053\/jinf.2000.0723","article-title":"Species-specific prevalence of vaginal candidiasis among patients with diabetes mellitus and its relation to their glycaemic status","volume":"41","author":"Goswami","year":"2000","journal-title":"J Infect"},{"key":"10.1016\/j.numecd.2016.07.006_bib48","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2334-2-1","article-title":"Prevalence and risk factors for vaginal Candida colonization in women with type 1 and type 2 diabetes","volume":"2","author":"De Leon","year":"2002","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.numecd.2016.07.006_bib49","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1001\/archderm.1990.01670320070011","article-title":"An argument for circumcision","volume":"126","author":"Fakjian","year":"1990","journal-title":"Arhc Dermatol"},{"key":"10.1016\/j.numecd.2016.07.006_bib50","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1001\/jama.291.11.1368","article-title":"Evaluation of vaginal complaints","volume":"291","author":"Anderson","year":"2004","journal-title":"JAMA"},{"issue":"9577","key":"10.1016\/j.numecd.2016.07.006_bib51","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1016\/S0140-6736(07)60917-9","article-title":"Vulvovaginal candidosis","volume":"369","author":"Sobel","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.numecd.2016.07.006_bib52","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s40064-014-0783-8","article-title":"The evaluation of microbiology and prognosis of Fournier's gangrene in past five years","volume":"4","author":"Tang","year":"2015","journal-title":"Springerplus"},{"key":"10.1016\/j.numecd.2016.07.006_bib53","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.diabres.2013.12.052","article-title":"Genital and urinary tract infections in diabetes: impact of pharmacologically-induced glucosuria","volume":"103","author":"Geerlings","year":"2014","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.numecd.2016.07.006_bib54","doi-asserted-by":"crossref","first-page":"e0125879","DOI":"10.1371\/journal.pone.0125879","article-title":"Comparative efficacy and safety of antidiabetic drug regimens added to metformin monotherapy in patients with type 2 diabetes: a network meta-analysis","volume":"10","author":"Mearns","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.numecd.2016.07.006_bib55","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1016\/j.clinthera.2015.03.004","article-title":"The role of sodium-glucose co-transporter 2 inhibitors in the treatment of type 2 diabetes","volume":"37","author":"Whalen","year":"2015","journal-title":"Clin Ther"},{"key":"10.1016\/j.numecd.2016.07.006_bib56","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.jdiacomp.2013.05.004","article-title":"Urinary tract infections in patients with diabetes treated with dapagliflozin","volume":"27","author":"Johnsson","year":"2013","journal-title":"J Diabetes Complicat"},{"key":"10.1016\/j.numecd.2016.07.006_bib57","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.jdiacomp.2013.04.012","article-title":"Vulvovaginitis and balanitis in patients with diabetes treated with dapagliflozin","volume":"27","author":"Johnsson","year":"2013","journal-title":"J Diabetes Complicat"},{"key":"10.1016\/j.numecd.2016.07.006_bib58","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1111\/dom.12459","article-title":"Long-term glycaemic response and tolerability of dapagliflozin versus a sulphonylurea as add-on therapy to metformin in patients with type 2 diabetes: 4-year data","volume":"17","author":"Del Prato","year":"2015","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.numecd.2016.07.006_bib59","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.2337\/dc14-0315","article-title":"Dapagliflozin's effects on glycemia and cardiovascular risk factors in high-risk patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled study with a 28-week extension","volume":"38","author":"Cefalu","year":"2015","journal-title":"Diabetes Care"},{"key":"10.1016\/j.numecd.2016.07.006_bib60","doi-asserted-by":"crossref","first-page":"365","DOI":"10.2337\/dc14-0666","article-title":"Dapagliflozin improves glycemic control and reduces body weight as add-on therapy to metformin plus sulfonylurea: a 24-week randomized, double-blind clinical trial","volume":"38","author":"Matthaei","year":"2015","journal-title":"Diabetes Care"},{"key":"10.1016\/j.numecd.2016.07.006_bib61","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s13300-014-0072-0","article-title":"Dapagliflozin added to glimepiride in patients with type 2 diabetes mellitus sustains glycemic control and weight loss over 48 weeks: a randomized, double-blind, parallel-group, placebo-controlled trial","volume":"5","author":"Strojek","year":"2014","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.numecd.2016.07.006_bib62","first-page":"212262","article-title":"Empagliflozin: a new sodium-glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes","volume":"3","author":"Neumiller","year":"2014","journal-title":"Drugs Context"},{"key":"10.1016\/j.numecd.2016.07.006_bib63","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/dom.12188","article-title":"Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial","volume":"16","author":"Kovacs","year":"2014","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.numecd.2016.07.006_bib64","doi-asserted-by":"crossref","first-page":"3396","DOI":"10.2337\/dc12-2673","article-title":"Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial","volume":"36","author":"H\u00e4ring","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1016\/j.numecd.2016.07.006_bib65","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.2337\/dc13-2105","article-title":"Empagliflozin as add-on to metformin in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial","volume":"37","author":"H\u00e4ring","year":"2014","journal-title":"Diabetes Care"},{"key":"10.1016\/j.numecd.2016.07.006_bib66","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.numecd.2016.07.006_bib67","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1185\/03007995.2012.697053","article-title":"Evaluation of vulvovaginal symptoms and Candida colonization in women with type 2 diabetes mellitus treated with canagliflozin, a sodium glucose co-transporter 2 inhibitor","volume":"28","author":"Nyirjesy","year":"2012","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.numecd.2016.07.006_bib68","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3810\/pgm.2014.05.2753","article-title":"Safety and tolerability of canagliflozin in patients with type 2 diabetes mellitus: pooled analysis of phase 3 study results","volume":"126","author":"Usiskin","year":"2014","journal-title":"Postgrad Med"},{"key":"10.1016\/j.numecd.2016.07.006_bib69","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1111\/dom.12428","article-title":"Long-term efficacy and safety of canagliflozin over 104 weeks in patients aged 55-80 years with type 2 diabetes","volume":"17","author":"Bode","year":"2015","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.numecd.2016.07.006_bib70","doi-asserted-by":"crossref","first-page":"355","DOI":"10.2337\/dc13-2762","article-title":"Canagliflozin provides durable glycemic improvements and body weight reduction over 104 weeks versus glimepiride in patients with type 2 diabetes on metformin: a randomized, double-blind, phase 3 study","volume":"38","author":"Leiter","year":"2015","journal-title":"Diabetes Care"},{"key":"10.1016\/j.numecd.2016.07.006_bib71","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1007\/s00125-013-3039-1","article-title":"Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial","volume":"56","author":"Lavalle-Gonz\u00e1lez","year":"2013","journal-title":"Diabetologia"}],"container-title":["Nutrition, Metabolism and Cardiovascular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939475316301132?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939475316301132?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,10]],"date-time":"2018-09-10T10:56:29Z","timestamp":1536576989000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939475316301132"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11]]},"references-count":71,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2016,11]]}},"alternative-id":["S0939475316301132"],"URL":"https:\/\/doi.org\/10.1016\/j.numecd.2016.07.006","relation":{},"ISSN":["0939-4753"],"issn-type":[{"value":"0939-4753","type":"print"}],"subject":[],"published":{"date-parts":[[2016,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Genitourinary infections in diabetic patients in the new era of diabetes therapy with sodium-glucose cotransporter-2 inhibitors","name":"articletitle","label":"Article Title"},{"value":"Nutrition, Metabolism and Cardiovascular Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.numecd.2016.07.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 The Italian Society of Diabetology, the Italian Society for the Study of Atherosclerosis, the Italian Society of Human Nutrition, and the Department of Clinical Medicine and Surgery, Federico II University. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}